Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Sugar-Enable

Financiado

Cerrado

Influenza Virus Sugar Interactions From Glycan Arrays To Better Vaccines

Our current assays to determine the receptor specificity and vaccine efficiency of influenza A virus fail as they do not represent receptors available in the human upper respiratory tract. The lack of these receptors in our labora... ver más

30/11/2023

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-11-30

ERC-2018-STG: ERC Starting Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

1.44M€ | Lider

SAGETIS BIOTECH

380.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UNIFLUVAC A novel universal influenza vaccine targeting epitopes of li... 149K€ Cerrado

GLYCAN CARTOGRAPHY Mapping of evolution and adaptation of the influenza virus h... 171K€ Cerrado

Sugar-enabledVAC Glycoengineered erythrocytes for better influenza vaccines 150K€ Cerrado

SAMUFLU Self amplifying RNA technology applied to the development of... 187K€ Cerrado

CARBOFLU Chemoenzymatic synthesis of complex glycans to decipher the... 178K€ Cerrado

GLYCOFLUP Probing Molecular Recognition of the Avian and Human Influen... 169K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2018-11-26
Fecha Fin: 2023-11-30

Líder del proyecto

UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Our current assays to determine the receptor specificity and vaccine efficiency of influenza A virus fail as they do not represent receptors available in the human upper respiratory tract. The lack of these receptors in our laboratory hosts to create vaccines significantly dampen yields, the resulting mismatched vaccines do not afford proper protection and further drive antigenic drift. The objective of this proposal is to elucidate the functional receptor of human influenza A viruses. By using antigenically drifted viruses, we expect to understand how glycan specificity changes due to immune pressure but it will also lead to the identification of a glycan that is utilized by all human IAV viruses. With this knowledge, better surveillance techniques, culture models and structure-based inhibitors can be developed. Using a novel and sophisticated cell-engineering tool, based on lipidated sugars, we will show functional glycan receptor usage. In addition, I will create cell lines in which human influenza A vaccine viruses grow to high titers without adaptation, thus providing superior protection. To achieve this goal, I propose to enzymatically synthesize complex glycans (AIM 1), including sialic acid modifications that are found on the respiratory tract epithelial cells of humans and other IAV hosts. Several enzymatic methods and glycan array tools are in place, and thus the chance of success is high. I already set-up preliminary methods for the use of lipidated N-glycan structures and extensive knowledge on SEEL is present in the department (AIM 2). For creating super vaccine producing cell lines I will use genetic approaches that previously have shown to be successful (AIM3). The systems dealing with sugars enabling function, either for infection or vaccine research, I term sugar-enable, will provide new endeavors to create glycan-analog inhibitors and will bring us steps closer to better vaccines.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores